You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
榮昌生物(09995.HK)預計2023年度營業收入增加約40%

格隆匯1月30日丨榮昌生物(09995.HK)公吿,經公司財務部門初步測算,預計2023年度營業收入約人民幣108,000萬元,與上年同期相比,將增加收入約人民幣31,000萬元,同比增加約40%。

公司預計2023年度實現歸屬於母公司所有者的淨虧損約人民幣155,000萬元,與上年同期相比,將增加虧損人民幣約55,200萬元,同比虧損增加約55%。

公司預計2023年度歸屬於母公司所有者扣除非經常性損益後的淨虧損約人民幣158,000萬元,與上年同期相比,將增加虧損人民幣約46,400萬元,同比虧損增加約42%。

雖然本年度泰它西普和維迪西妥單抗銷售收入快速增長,但由於公司新藥研發管線持續推進,多個創新藥物處於關鍵試驗研究階段,研發投入仍然保持較高水平。同時,為拓展市場,公司商業化投入較多的團隊建設費用和學術推廣活動開支。因此,預計公司2023年度錄得淨虧損,扣除非經常性損益前後均虧損。

本年度非經常性損益總額減少,主要是由於收到的計入當年損益的政府補助減少

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account